AQP4 and neuromyelitis optica: In total 4/5 (80%) of the AQP4 seropositive NMO patients had serum NfHSMI35 levels above the highest value observed in the control cohort (0.05 ng/mL, horizontal dotted line in Figures 2 and 3).